카리스마 테라퓨틱스(CARM)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $0.00 (+0.00%), 시가총액 $4,184, PER 0.00, 52주 범위 $0.00 ~ $1.11.
Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidates include CT-2401, which is in preclinical trial for the treatment of liver fibrosis. The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in phase I clinical trial to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others. In addition, it develops in vivo CAR-M cell therapy to treat solid tumors, including hepatocellular carcinoma. Carisma Therapeutics, Inc.
카리스마 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 XTS에서 실시간으로 확인할 수 있습니다.
카리스마 테라퓨틱스의 현재 주가는 $0.00 (+0.00%)입니다. XTS에서 실시간 시세와 차트를 확인할 수 있습니다.
카리스마 테라퓨틱스의 시가총액은 약 $4,184입니다. PER은 0.00입니다.
Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States.